has a long half-life allowing for once-daily dosing in treatment-naive patients and has less pharmacokinetic variability compared with other HIV INSTIs. For treatment-naive patients, dolutegravir ...

2024 — Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy ...

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ongoing efforts to curtail an epidemic. Confronting the HIV Epidemic: There's an App ...